What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several year...
Auteurs principaux: | Testa, L, Bhindi, R, Van Gaal, W, Latini, R, Pizzocri, S, Lanotte, S, Biondi Zoccai, G, Valgimigli, M, Laudisa, M, Brambilla, N, Banning, A, Bedogni, F |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2010
|
Documents similaires
-
Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis.
par: Testa, L, et autres
Publié: (2010) -
Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
par: L. Testa, et autres
Publié: (2010-01-01) -
Use of prasugrel in patients with clopidogrel hypersensitivity
par: Aparna Joshi, et autres
Publié: (2022-01-01) -
Interaction between statins and clopidogrel: is there anything clinically relevant?
par: Bhindi, R, et autres
Publié: (2008) -
Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition.
par: Testa, L, et autres
Publié: (2009)